Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
21-40 of 3,900 trials

Chronic Pain in Children: Capsaicin Patch Study

We are investigating whether a capsaicin patch can help relieve chronic pain in children aged 12 to 17 after surgery or injury. The study will also look at how well the treatment is tolerated and its effects on other pain medications.

Chronic Neuropathic Pain3-6 monthsConfirmation phase (III)Investigational MedicinesNeurologyPediatrics

Epidermolysis Bullosa: ABCB5+ Stem Cell Treatment

We are studying a new stem cell therapy for individuals with recessive dystrophic epidermolysis bullosa. The trial aims to see if this treatment is safe and effective compared to a placebo.

Epidermolysis Bullosa1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal Medicine

End-Stage Kidney Disease: CSL300 Treatment Study

We are investigating whether different doses of CSL300 can help reduce inflammation in adults with end-stage kidney disease undergoing dialysis. This study aims to understand its potential effects on heart health.

Atherosclerotic Cardiovascular Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineNephrology

Ulcerative Colitis: SAR443122 Study

We are testing different doses of SAR443122 in adults with moderate to severe ulcerative colitis to see how well it works and its safety. The study will also look at improvements in symptoms and quality of life.

Ulcerative Colitis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Parkinson's Disease: ACI-7104.056 Vaccine Study

We are testing a new vaccine to see if it is safe and can help improve symptoms in people with early-stage Parkinson's disease. The study will also look at how the vaccine affects certain biological markers related to the disease.

Early Stages of Parkinson's Disease>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Preventing Bronchopulmonary Dysplasia: New Treatment for Preterm Newborns

We are studying a new therapy using cell-derived vesicles to see if it can help prevent lung problems in extremely preterm newborns. This trial will assess both safety and effectiveness compared to a placebo.

Bronchopulmonary Dysplasia>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesPediatricsPulmonology

Acute Myeloid Leukemia: CPX-351 vs. Standard Chemotherapy

We are studying whether a new treatment called CPX-351 can help patients with specific types of acute myeloid leukemia achieve better remission compared to standard chemotherapy. This trial focuses on patients with de novo intermediate or adverse risk AML.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Kidney Transplant: Belatacept vs. Traditional Immunosuppressants

We are studying if replacing standard medications with belatacept helps kidney transplant patients with early graft dysfunction. The goal is to see if this approach improves kidney function and reduces rejection risks.

Kidney Transplant1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesNephrology

Chronic Lymphocytic Leukemia: Venetoclax and Epcoritamab Study

We are studying a combination of venetoclax and epcoritamab in patients with relapsed or refractory CLL or SLL. The goal is to see if this treatment improves disease control and overall survival compared to existing options.

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Uveal Melanoma: Adjuvant Melatonin Study

We are investigating whether nightly melatonin can help reduce the spread of uveal melanoma and improve survival rates. This study is for patients diagnosed with this type of eye cancer.

Uveal MelanomaConfirmation phase (III)No PlaceboStandard MedicinesOncologyOphthalmology

Crohn's Disease: Comparing Biological Therapies After Surgery

We are studying two ways to start biological therapy after surgery for Crohn's disease to see which better prevents disease recurrence. This trial involves adults who have had an ileocolonic resection.

Crohn's Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyInternal Medicine

Etripamil Nasal Spray for Pediatric Heart Condition

We are studying whether a nasal spray can help stop episodes of a fast heart rate in children aged 6 to 17. The trial also looks at how safe the spray is for these young patients.

Paroxysmal Supraventricular Tachycardia≤3 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCardiologyPediatrics

Etrasimod for Adolescents with Ulcerative Colitis

We are studying whether etrasimod can help adolescents aged 12 to 17 with moderately to severely active ulcerative colitis achieve remission. The trial will also look at the safety and how the body processes the medication.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Postoperative Pain Management: Genetic Testing for Tramadol

We are studying whether genetic testing can help tailor tramadol treatment for better pain relief and fewer side effects after surgery. This trial also compares tramadol with another pain medication to find the most effective option.

PharmacogeneticsTherapeutic Techniques for Acute Postoperative PainMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurologyPsychiatry

Heart Attack Recovery: Dabigatran vs. Vitamin K Antagonist

We are studying whether the medication Dabigatran helps patients with blood clots in the heart after a heart attack recover better than a traditional treatment. This trial looks at how well each treatment resolves the clot and prevents complications.

STEMI (ST Elevation Myocardial Infarction)Left Ventricular Thrombosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Febrile Neutropenia: SAFE Study on Short Antibiotic Treatment

We are studying whether stopping antibiotics after 3 days is as safe as continuing them longer for patients with febrile neutropenia. This research aims to find a potentially safer treatment approach for hematology patients.

Febrile Neutropenia>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

Peripheral T-Cell Lymphoma: Tolinapant with Decitabine/Cedazuridine

We are studying a new treatment combining tolinapant with oral decitabine/cedazuridine for patients with relapsed or refractory peripheral T-cell lymphoma. The goal is to assess safety and effectiveness compared to the current standard treatment.

T-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Risankizumab for Moderate to Severe Plaque Psoriasis in Children and Teens

We are studying the long-term safety and effectiveness of risankizumab in children and teens aged 6 to 17 with moderate to severe plaque psoriasis. This follows their participation in a previous study to see how well the treatment works over time.

Plaque Psoriasis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyDermatology

Cardiac Surgery: Vasopressin vs. Norepinephrine

We are comparing two medications to see which better protects kidney function and reduces complications in patients at risk during cardiac surgery. This study aims to improve outcomes for those undergoing surgery with heart-lung machines.

Vasoplegic Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyInternal MedicineNephrologyOtolaryngology

Anemia in Low-Risk Myelodysplastic Syndrome: Luspatercept vs Epoetin Alfa

We are comparing a new treatment, luspatercept, with a standard treatment, epoetin alfa, for patients with low-risk myelodysplastic syndrome who do not need blood transfusions. The goal is to see which treatment better helps manage anemia.

Myelodysplastic Syndrome (MDS)>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine